Praluent Cost in Connecticut 2026: Prices, Insurance, Medicaid, and Compounding

What Is Alirocumab and Why Does It Cost So Much?

Alirocumab is a fully human monoclonal antibody that blocks PCSK9, the protein that degrades LDL receptors in the liver. Fewer functioning LDL receptors mean higher circulating LDL-cholesterol. By neutralizing PCSK9, alirocumab allows the liver to recycle more receptors and clear more LDL from the blood. In the key ODYSSEY LONG TERM trial (N=2,341), alirocumab 150 mg every two weeks reduced LDL-C by 62% from baseline at 24 weeks compared with placebo 1.

The high list price reflects the cost of biologic manufacturing. Unlike small-molecule statins, monoclonal antibodies require mammalian cell culture, protein purification, and cold-chain distribution. Regeneron and Sanofi set the U.S. wholesale acquisition cost (WAC) for Praluent at approximately $580 per month in 2026 for a twice-monthly 75 mg or 150 mg regimen. That figure has barely changed since Regeneron and Sanofi reduced the price from over $14,000 per year in 2018 in response to payer pressure 2.

The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering on maximally tolerated statin therapy. The full prescribing information is available on the FDA label page 3.

Praluent Cash Price in Connecticut in 2026

The cash price at Connecticut retail pharmacies runs close to the WAC. Expect to pay $570 to $600 per month without insurance or a savings program. Regional pharmacy chains and independents do not discount biologics the way they discount generic statins, so there is little variation across CVS, Walgreens, and independent pharmacies in Hartford, New Haven, or Stamford.

At $580 per month, an uninsured Connecticut resident would spend roughly $6,960 per year on Praluent. That figure makes cash-pay access effectively impossible for most patients without assistance. The American Heart Association has called the price barrier a "major impediment to evidence-based lipid management," noting that fewer than 50% of eligible patients fill a PCSK9 inhibitor prescription within one year of a qualifying cardiovascular event 4.

For context, rosuvastatin 40 mg, the maximally tolerated statin for many patients, costs $15 to $30 per month at Connecticut pharmacies using GoodRx. Ezetimibe adds another $15 to $25. Before prescribing alirocumab, most Connecticut clinicians document failure or intolerance of at least two statins plus ezetimibe, partly because that history is required for insurance prior authorization and partly because it is good clinical practice.

Connecticut Medicaid Coverage for Praluent

Connecticut Medicaid (HUSKY Health) covers alirocumab with prior authorization for members who meet clinical criteria. The program follows criteria broadly aligned with the 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction 5. Covered indications include:

• Heterozygous familial hypercholesterolemia (HeFH) with LDL-C at or above 130 mg/dL on maximally tolerated statin therapy.
• Clinical ASCVD (prior MI, stroke, or peripheral arterial disease) with LDL-C at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe.
• Statin intolerance documented by muscle toxicity or elevated CK on two separate statins.

The PA process in Connecticut typically requires a prescribing physician or advanced practice provider to submit medical records, a current lipid panel, documentation of prior statin trials, and a statement of ASCVD risk. Processing times average 3 to 14 business days. If the PA is denied, Connecticut Medicaid allows one level of internal appeal and one external independent review, each with statutory timeframes.

Medicaid members whose PA is approved pay $0 to $3 per fill, depending on their specific HUSKY plan tier. Connecticut expanded Medicaid under the ACA; approximately 920,000 residents were enrolled in HUSKY Health as of January 2025, according to the CT Office of Policy and Management.

Homozygous FH (HoFH) is a separate indication. Alirocumab monotherapy produces more modest LDL reductions in HoFH patients because many have virtually no functional LDL receptors. For HoFH, lomitapide or evinacumab are often preferred, but alirocumab may still be authorized as adjunctive therapy in Connecticut Medicaid on a case-by-case basis 6.

The ODYSSEY OUTCOMES Trial: Why Alirocumab Is Approved for ASCVD

Understanding what the clinical evidence says matters when appealing a denied PA. ODYSSEY OUTCOMES enrolled 18,924 patients with acute coronary syndrome (ACS) in the prior 1 to 12 months and randomized them to alirocumab 75 mg every two weeks (titrated to 150 mg if LDL-C remained above 50 mg/dL) or placebo, on top of high-intensity statin therapy 7.

At a median follow-up of 2.8 years, the alirocumab group had a 15% relative risk reduction in the primary composite endpoint of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization (9.5% vs. 11.1%; HR 0.85 to 95% CI 0.78 to 0.93; P<0.001) 7. All-cause mortality was also numerically lower with alirocumab (3.5% vs. 4.1%), a difference that reached statistical significance in the pre-specified subgroup with baseline LDL-C at or above 100 mg/dL.

The number needed to treat (NNT) to prevent one primary event over 2.8 years was approximately 63. For a drug costing $6,960 per year, that translates to roughly $437,000 per event prevented at list price, which helps explain why payers impose PA requirements. When rebates bring the net price to 40 to 60% of WAC, the cost-effectiveness ratio improves substantially, and ICER analyses have found alirocumab cost-effective at the reduced price 8.

Praluent Insurance Coverage in Connecticut: Commercial Plans

Most major commercial insurers operating in Connecticut (Aetna, UnitedHealthcare, Cigna, Anthem/BCBS of CT, ConnectiCare, Harvard Pilgrim) cover Praluent on specialty tier formularies. The drug appears on Tier 4 or Tier 5 in most plan designs, meaning coinsurance rates of 25 to 33% apply before the deductible is met and out-of-pocket maximums kick in.

A patient on a plan with a $4,500 deductible and 25% specialty coinsurance could pay $1,450 out of pocket before meeting the deductible, then nothing further until the plan year resets. The Regeneron/Sanofi copay savings card (see below) offsets much of that burden for commercially insured patients.

Step therapy is common. Most Connecticut commercial plans require documentation of an adequate statin trial (at least 4 to 12 weeks at maximum tolerated dose) before approving Praluent. Some plans also require an ezetimibe trial. The 2022 ACC/AHA Guideline states: "For patients with ASCVD who are at very high risk and whose LDL-C remains >=70 mg/dL on maximally tolerated statin plus ezetimibe, it is reasonable to add a PCSK9 inhibitor" 5, a passage that supports medical necessity appeals.

Patients denied coverage by a commercial insurer have 180 days from the denial notice to file an internal appeal under Connecticut state law (CGS Sec. 38a-591). If the internal appeal fails, an external independent review is available for adverse benefit determinations involving medical necessity. Connecticut's Insurance Department maintains a complaint process that can expedite external review in urgent cases.

The Regeneron/Sanofi Savings Card in Connecticut

Regeneron and Sanofi offer a copay assistance program for commercially insured U.S. patients, including those in Connecticut. Eligible patients may pay $0 per month, up to a defined annual benefit maximum. As of 2026, the program caps savings at $14,400 per year ($1,200 per month), which covers the full list price for most patients.

Key eligibility rules:

• Commercial or private insurance required. Medicare, Medicaid, CHIP, and other government programs are excluded.
• Patient must be a U.S. resident and not in a state that prohibits manufacturer copay assistance (Connecticut does not restrict it).
• The prescribing provider must participate by submitting the enrollment form or directing the patient to the Praluent.com enrollment portal.

The savings card is processed at the pharmacy like a secondary insurance card. The pharmacist runs the primary plan first, then the copay card covers the remaining balance up to the program limit. Patients receive a card or an e-card with a BIN/PCN/Group number.

For patients whose commercial plan excludes Praluent entirely or denies PA, the savings card does not apply at the pharmacy. In those cases, the manufacturer's patient assistance program (PAP), which provides free drug directly to qualifying uninsured or underinsured patients, is a separate avenue. Income eligibility thresholds for the PAP are typically at or below 600% of the federal poverty level, though exact thresholds change annually.

Compounded Alirocumab in Connecticut: Legal Status and Cost

Compounded alirocumab is a legally available option in Connecticut through state-licensed 503A compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drugs based on a valid patient-specific prescription from a licensed prescriber 9. Alirocumab is not on the FDA's list of drugs that may not be compounded (the "do-not-compound" list), so 503A pharmacies in Connecticut may legally prepare it.

The practical implications are significant. Several telehealth-affiliated compounding pharmacies offer alirocumab at $0 per month for patients enrolled through specific programs, or at a substantially lower out-of-pocket cost than branded Praluent. The active pharmaceutical ingredient used in compounding is synthesized separately from the Regeneron/Sanofi manufacturing process.

Patients and prescribers should understand several points:

• Compounded biologics are not FDA-approved finished drug products. Bioequivalence testing required for small-molecule generic drugs does not apply to compounded biologics.
• Quality varies by pharmacy. Connecticut's Department of Consumer Protection, Pharmacy Unit, inspects 503A pharmacies and enforces USP <797> and <800> sterile compounding standards 10.
• Insurance typically does not cover compounded alirocumab. Cash-pay or program pricing applies.
• Some telehealth platforms bundle the provider visit fee and the compounded medication cost, making the net patient cost $0 per month in promotional programs.

The FDA has noted concerns about compounded versions of complex biologics, stating in guidance that "biological products present unique considerations for compounding because of their complexity and sensitivity" 11. Patients choosing compounded alirocumab should confirm the pharmacy's accreditation with PCAB (Pharmacy Compounding Accreditation Board) and ask for a certificate of analysis for each lot.

Telehealth Prescribing of Praluent in Connecticut

Connecticut law permits telehealth prescribing of alirocumab for both new and established patients. The Connecticut Telehealth Act (CGS Sec. 19a-906) requires that the prescriber hold a valid Connecticut license or a qualifying compact license, that the telehealth encounter meet the same standard of care as an in-person visit, and that a patient-prescriber relationship be established during the encounter.

For PCSK9 inhibitors specifically, a telehealth clinician must still satisfy the same clinical criteria that a PA requires: documented ASCVD or FH diagnosis, recent lipid panel, and evidence of prior statin therapy. Remote prescribing does not waive insurance PA requirements. However, telehealth platforms that offer compounded alirocumab can bypass the commercial insurance PA process entirely, since the prescription goes directly to a compounding pharmacy.

The American College of Cardiology has published guidance on remote lipid management, noting that telehealth visits are appropriate for lipid therapy initiation and follow-up when in-person monitoring is not feasible 12. LDL-C monitoring every 4 to 12 weeks after starting alirocumab can be done via mail-order or walk-in lab services without requiring an in-person clinic visit.

How Alirocumab Dosing Affects Monthly Cost

Alirocumab comes in two dose levels. The 75 mg subcutaneous injection every two weeks is the starting dose for most patients. If LDL-C response is insufficient after 4 to 8 weeks, the dose may be increased to 150 mg every two weeks. A 300 mg monthly injection (delivered as two 150 mg injections at the same visit) is FDA-approved as an alternative regimen.

The monthly cost does not change with dose escalation for branded Praluent because the savings card and insurance benefit apply to the prescription regardless of strength. For compounded alirocumab, the cost per milligram may differ, so patients switching from 75 mg to 150 mg twice monthly should confirm pricing with their compounding pharmacy before escalating.

Both the 75 mg/mL and 150 mg/mL formulations are delivered via a single-dose pre-filled pen or pre-filled syringe. The pen device requires no reconstitution and can be self-injected at home after one training session. Injection site reactions occurred in 7.2% of alirocumab-treated patients versus 5.1% of placebo patients in ODYSSEY LONG TERM, making them common but rarely treatment-limiting 1.

LDL Goals and Who Qualifies for Alirocumab in Connecticut

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction recommends alirocumab or evolocumab for very high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL on maximum-dose statin plus ezetimibe, assigning this a Class IIa recommendation (Level of Evidence A) 5. Very high risk is defined as a history of multiple major ASCVD events or one major event plus high-risk conditions (age <55 in men or <65 in women, HeFH, prior CABG or PCI, diabetes, hypertension, CKD stage 3 or 4, current smoking, or persistent LDL-C at or above 100 mg/dL).

For HeFH patients, the European Atherosclerosis Society Consensus Panel recommends an LDL-C target below 70 mg/dL for those with established ASCVD and below 100 mg/dL for those without, criteria Connecticut Medicaid PA forms closely mirror 13.

Alirocumab reduces LDL-C by 45 to 62% on top of background statin therapy, depending on the trial and dose 1. A patient starting with an LDL-C of 120 mg/dL on rosuvastatin 40 mg plus ezetimibe might expect to reach 45 to 66 mg/dL on alirocumab 150 mg, comfortably below the 70 mg/dL very high-risk threshold.

Practical Checklist for Connecticut Patients Starting Alirocumab

Getting Praluent or compounded alirocumab covered in Connecticut involves several sequential steps. Working through them methodically saves time.

First, confirm the diagnosis code. Payers and compounding pharmacies both need an ICD-10 code: E78.01 for HeFH, or Z82.49 plus the relevant ASCVD code (I25.10 for CAD, I63.9 for stroke, etc.).

Second, obtain a current lipid panel drawn within 90 days. Most insurers require a fasting specimen; some accept non-fasting for repeat monitoring.

Third, document two statin trials at maximally tolerated doses, with dates and LDL-C results on each. Include any creatine kinase levels that supported a myopathy diagnosis if claiming statin intolerance.

Fourth, submit the PA package. For Connecticut Medicaid, use the HUSKY Health prior authorization form. For commercial plans, use the insurer's specialty pharmacy PA portal or fax form. Attach the lipid panel, medication history, and ASCVD documentation.

Fifth, while the PA is pending, apply for the Regeneron/Sanofi savings card or patient assistance program so coverage begins immediately upon approval. Processing takes two to five business days.

If the PA is denied, request the denial letter and specific clinical rationale, then submit a peer-to-peer review request. Cardiologists and lipidologists who conduct peer-to-peer calls with payer medical directors report a reversal rate above 60% in internal audits at academic lipid clinics 14.

Comparing Alirocumab to Evolocumab in Connecticut

Evolocumab (Repatha, Amgen) is the other approved PCSK9 inhibitor in the U.S. market. Its list price in 2026 is approximately $585 per month, marginally higher than alirocumab. Both drugs are covered under similar Connecticut Medicaid PA criteria, and both have commercial copay assistance programs with comparable benefit caps.

Head-to-head data comparing alirocumab and evolocumab on cardiovascular outcomes do not exist. The FOURIER trial (N=27,564) showed evolocumab reduced major cardiovascular events by 15% over 2.2 years (HR 0.85 to 95% CI 0.79 to 0.92; P<0.001), a magnitude almost identical to ODYSSEY OUTCOMES 15. Formulary placement, not clinical differentiation, typically determines which agent a Connecticut insurer prefers. Checking the specific plan formulary before prescribing saves a PA cycle.

Inclisiran (Leqvio, Novartis), a small interfering RNA drug that requires only twice-yearly injection, is a newer alternative. Its list price is higher, but its dosing convenience makes adherence easier. Connecticut Medicaid and most commercial plans cover inclisiran with PA under similar criteria.